Staidson (Beijing) BioPharmaceuticals Co., Ltd. Share Price
Equities
300204
CNE100001237
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 CNY | -2.17% | +11.50% | -37.99% |
Sales 2022 | 549M 75.77M 6.32B | Sales 2023 | 364M 50.26M 4.19B | Capitalization | 4.85B 670M 55.86B |
---|---|---|---|---|---|
Net income 2022 | -197M -27.19M -2.27B | Net income 2023 | -399M -55.07M -4.59B | EV / Sales 2022 | 11.2 x |
Net cash position 2022 | 259M 35.76M 2.98B | Net cash position 2023 | 44.23M 6.1M 509M | EV / Sales 2023 | 13.2 x |
P/E ratio 2022 |
-33.2
x | P/E ratio 2023 |
-12.1
x | Employees | 555 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 25.45% |
1 day | -2.17% | ||
1 week | +11.50% | ||
Current month | -6.80% | ||
1 month | -5.55% | ||
3 months | -27.84% | ||
6 months | -37.62% | ||
Current year | -37.99% |
Managers | Title | Age | Since |
---|---|---|---|
Chao Wang
CEO | Chief Executive Officer | 42 | 01/11/01 |
Shi Cheng Li
DFI | Director of Finance/CFO | 42 | 26/20/26 |
Zhi Wen Zhou
PSD | President | 59 | 01/02/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Hong Shan Zhang
CHM | Chairman | 60 | 01/02/01 |
Zhi Wen Zhou
CHM | Chairman | 59 | 01/02/01 |
Tao Li
BRD | Director/Board Member | 61 | 01/08/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 6.3 | -2.17% | 13,344,480 |
25/24/25 | 6.44 | +8.60% | 20,493,430 |
24/24/24 | 5.93 | +0.68% | 3,745,100 |
23/24/23 | 5.89 | +2.43% | 5,902,655 |
22/24/22 | 5.75 | +1.77% | 4,771,600 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-37.99% | 415M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- 300204 Stock